← Back to Search

Stem Cell Therapy

human retinal progenitor cells for Retinitis Pigmentosa

Phase 2
Waitlist Available
Led By Mitul Mehta, MD
Research Sponsored by jCyte, Inc
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 months
Awards & highlights

Summary

This study is evaluating whether a new treatment for retinitis pigmentosa is safe.

Eligible Conditions
  • Retinitis Pigmentosa

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Safety of Intravitreal Injection of hRPC
Secondary outcome measures
Best Corrected Visual Acuity
Contrast Sensitivity
Mobility
+1 more

Side effects data

From 2020 Phase 2 trial • 84 Patients • NCT03073733
17%
Conjunctival hemorrhage
10%
Visual acuity reduced
7%
Influenza
7%
Localised infection
3%
Cystoid macular edema
3%
Sinusitis
3%
Intraocular pressure increased
100%
80%
60%
40%
20%
0%
Study treatment Arm
Sham Treated Control
Test (jCell Injection) Dose Level 1
Test (jCell Injection) Dose Level 2

Trial Design

1Treatment groups
Experimental Treatment
Group I: Retreated subjectsExperimental Treatment1 Intervention
Subjects receiving human retinal progenitor cells (jCell) who have previously received jCell is a jCyte study.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
human retinal progenitor cells
2015
Completed Phase 2
~150

Find a Location

Who is running the clinical trial?

California Institute for Regenerative Medicine (CIRM)OTHER
65 Previous Clinical Trials
3,145 Total Patients Enrolled
3 Trials studying Retinitis Pigmentosa
128 Patients Enrolled for Retinitis Pigmentosa
jCyte, IncLead Sponsor
2 Previous Clinical Trials
112 Total Patients Enrolled
2 Trials studying Retinitis Pigmentosa
112 Patients Enrolled for Retinitis Pigmentosa
Mitul Mehta, MDPrincipal InvestigatorUniversity of California, Irvine/Gavin Herbert Eye Institute
2 Previous Clinical Trials
104 Total Patients Enrolled
1 Trials studying Retinitis Pigmentosa
84 Patients Enrolled for Retinitis Pigmentosa
~7 spots leftby Jul 2025